C-Peptide: Connecting diabetes with macrovascular complications

Karen E. Porter, Romana S. Mughal

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Citation (Scopus)


The incidence of diabetes is increasing globally; the estimated prevalence in 2010 being 285 million worldwide (www.http://diabetes.org.uk). In the UK alone, the number of people diagnosed with diabetes has increased from 1.4 to 2.6 million since 1996 (www.http://diabetes.org.uk). These individuals are at high risk of cardiovascular disease and in this population coronary artery disease (CAD) is common, regularly manifesting itself earlier in life than in individuals without diabetes [1]. While strategies that maintain tight glucose control have been reported to ameliorate some of the microvascular complications of diabetes (retinopathy, nephropathy, neuropathy) [2], this approach appears to have little or no benefit in the macrovasculature [3]. A greater understanding of the complexity of the diabetic milieu may therefore be invaluable in exposing therapeutic targets to reduce the incidence of macrovascular diseases in diabetes.
Original languageEnglish
Title of host publicationDiabetes & C-Peptide: Scientific and Clinical Aspects
EditorsAnders A.F. Sima
PublisherHumana Press Inc.
Number of pages16
ISBN (Electronic)9781617793912
ISBN (Print)9781617793905
Publication statusPublished - 28 Oct 2011
Externally publishedYes


Dive into the research topics of 'C-Peptide: Connecting diabetes with macrovascular complications'. Together they form a unique fingerprint.

Cite this